KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Receivables: 2009-2024

Historic Receivables for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Dec 2024 value amounting to $405.3 million.

  • Alnylam Pharmaceuticals' Receivables rose 172.65% to $964.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 billion, marking a year-over-year increase of 79.45%. This contributed to the annual value of $405.3 million for FY2024, which is 23.65% up from last year.
  • Alnylam Pharmaceuticals' Receivables amounted to $405.3 million in FY2024, which was up 23.65% from $327.8 million recorded in FY2023.
  • Alnylam Pharmaceuticals' 5-year Receivables high stood at $602.4 million for FY2020, and its period low was $198.6 million during FY2021.
  • Moreover, its 3-year median value for Receivables was $327.8 million (2023), whereas its average is $323.7 million.
  • In the last 5 years, Alnylam Pharmaceuticals' Receivables spiked by 1,300.60% in 2020 and then plummeted by 67.04% in 2021.
  • Over the past 5 years, Alnylam Pharmaceuticals' Receivables (Yearly) stood at $602.4 million in 2020, then slumped by 67.04% to $198.6 million in 2021, then climbed by 19.84% to $238.0 million in 2022, then soared by 37.75% to $327.8 million in 2023, then rose by 23.65% to $405.3 million in 2024.